COMMENTARY

Open Access

Saul Hertz, MD, and the birth of radionuclide therapy



Frederic H. Fahey^{1,2*}, Frederick D. Grant^{1,2,3} and James H. Thrall^{1,4}

* Correspondence:

frederic.fahey@childrens.harvard.edu ¹Department of Radiology, Harvard Medical School, Boston, MA, USA ²Department of Radiology, Boston Children's Hospital, Boston, MA, USA Full list of author information is available at the end of the article

Abstract

The year, 2016, marked the 75th anniversary of Dr. Saul Hertz first using radioiodine to treat a patient with thyroid disease. In November of 1936, a luncheon was held of the faculty of Harvard Medical School where Karl Compton, PhD, president of the Massachusetts Institute of Technology was invited to give a presentation entitled "What Physics Can Do for Biology and Medicine." Saul Hertz who attended the luncheon spontaneously asked the very pertinent question that perhaps changed the course of treatment of thyroid disease, "Could iodine be made radioactive artificially?" We review the events leading up to the asking of this question, the preclinical investigations by Dr. Hertz and his colleague Arthur Roberts prior to the treatment of the first patient and what occurred in the years following this landmark event. This commentary seeks to set the record straight to the sequence of events leading to the first radioiodine therapy, so that those involved can be recognized with due credit.

Keywords: History, Saul Hertz, Radioiodine therapy

Background

The year, 2016, marked the 75th anniversary of Dr. Saul Hertz first using radioiodine to treat a patient with thyroid disease. In honor of this anniversary, we have spent a bit of time researching this wonderful advance, including what led up and was subsequent to this event. The excellent and informative history of nuclear medicine presented in 2014 by Peter Ell [1] describes a conversation between Howard Means of the Massachusetts General Hospital (MGH) and Robley Evans of the Massachusetts Institute of Technology (MIT) that most likely did not occur. This misunderstanding is not surprising, given that many versions of these events have been presented and published over the years. In this commentary, we hope to set the record straight to the sequence of events leading to the first radioiodine therapy, so that those involved can be recognized with due credit.


On November 12, 1936, Karl Compton, president of MIT, was invited to give a presentation at a luncheon of the faculty of Harvard Medical School. His topic was "What Physics Can Do for Biology and Medicine." Karl Compton was a physicist and the older brother of Arthur Compton, noted for characterizing the photon interaction that came to be known as "Compton scattering." Dr. Compton had been appointed president of MIT in 1930. It is likely that, during his presentation, Compton touched upon the recent production of artificial radioactivity by Frederic and Iréne Joliot Curie [2].



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

During the luncheon, Saul Hertz who was in attendance spontaneously asked the very pertinent question that perhaps changed the course of treatment of thyroid disease, "Could iodine be made radioactive artificially?" Saul Hertz was born in 1905 in Cleveland, Ohio. He received his undergraduate degree from the University of Michigan and received his MD degree from Harvard Medical School in 1929. After 2 years of post-graduate training at Mount Sinai Hospital in Cleveland, he returned to Boston in 1931, where he was appointed chief of the thyroid clinic at the MGH. The conversation between Drs. Compton and Hertz can be confirmed by an exchange of letters in the weeks following the luncheon (Fig. 1). It is clear from the letter of Compton that the conversation about the possibility of radioactive iodine was between Drs. Compton and Hertz.

This exchange between Hertz and Compton depended on more than 100 years of prior scientific advances in a number of disparate scientific fields. In 1811, the French chemist Bernard Courtois extracted iodine from the ashes of seaweed. Joseph Louis Gay-Lussac recognized the vapor from the Courtois experiment as a new element and named it "iodine" given its violet color. In 1851, Chatin demonstrated that endemic goiter was associated with low levels of iodine in the drinking water. Kocher significantly improved the surgical approaches to treating thyroid disease and, in 1909, won the Nobel Prize in Medicine and Physiology for his work on the physiology, pathology, and surgery of the thyroid gland. In 1895, Eugen Bauman demonstrated that the thyroid contains iodoprotein, which he called "thyroiodine", that contained 10–15% iodine and that administration of thyroiodine could reverse myxedema. In 1911, David Marine utilized iodine repletion to treat endemic goiter and treated hyperthyroidism with iodine. In 1922, Means investigates the use of X-rays to treat toxic goiter [3].




In 1896, Henri Bequerel demonstrates that the uranium salts with which he was working emitted radiation similar to the "new kind of rays" that Röntgen had produced with the use of a cathode ray tube just months earlier. Working in Bequerel's laboratory, Pierre Curie and Marie Sklodowska Curie isolated the naturally occurring radioactive elements polonium and radium. For these accomplishments, Bequerel and Pierre and Marie Curie shared the 1903 Nobel Prize in Physics. In 1923, George de Hevesy demonstrates the tracer principle through his work using radioactive indicators to investigate the absorption and translocation of lead in plants for which he won the Nobel Prize in 1943 [4]. In 1934, Frederic and Iréne Joliot Curie demonstrate the production of artificial radioactivity through their experiments of irradiation of lower Z elements with alpha particles [2]. After alpha irradiation of aluminum, the resultant positrons are emitted, not instantaneously, but with a 2.5 min half-life. They recognize that this phenomenon demonstrates the presence of a new radioactive entity (phosphorus-30). For this accomplishment, Frederic and Iréne Joliot Curie were awarded the 1935 Nobel Prize in Chemistry. Iréne Joliot Curie was the daughter of Marie Curie leading to the only mother-daughter and the 2nd husband-wife (after her parents) recipients of the Nobel Prize.

This collection of scientific accomplishments over the span of the previous 100 years set the stage for Dr. Hertz's question and the subsequent developments that led to treating the first patient with radioiodine. There are several notable points in the exchange between Drs. Compton and Hertz. Dr. Compton states that iodine can be made artificially radioactive with a half-life of 25 min. Thus, he is referring to ¹²⁸I, which, at that time, could be produced by neutron activation of ¹²⁷I, which had been demonstrated by Enrico Fermi. Dr. Hertz states in his reply to Compton that radioactive iodine may be "a useful method of therapy in cases of overactivity of the thyroid gland." This extraordinary hypothesis may have been built upon the earlier work by Means regarding the potential treatment of thyroid disease using external X-rays [3].

In the coming years, Dr. Hertz partnered with Arthur Roberts, a young faculty member of the Physics Department of MIT. Their initial work was performed with I¹²⁸ produced using a radium-beryllium (Ra-Be) neutron source to irradiate ¹²⁷I at the MIT Radioactivity Center, which was under the direction of Robley Evans. Utilizing ¹²⁸I, Hertz and Roberts were able to perform the initial biokinetic studies of iodine in rabbits (Fig. 2) and were able to published their findings in 1938 [5]. Although Robley Evans directed the laboratory that provided the radioiodine, the biodistribution studies were performed and analyzed solely by Drs. Hertz and Roberts. At the same time, a group at the University of California in Berkeley led by Joseph Hamilton was performing biodistribution studies of radiosodium and radioiodine [6, 7].

It soon became clear from these biokinetic studies that a radioiodine isotope with a 25-min half-life and the amounts of radioiodine that could be produced with the Ra-Be source would not be optimal for therapeutic applications. 10 years earlier, Ernest Lawrence and his team in Berkeley had developed the cyclotron for various investigations in nuclear physics. After the Joliot Curie paper, it became obvious that the cyclotron also could be used for generating artificial radioactivity. Drs. Compton, Evans, and Means petitioned the Markle Foundation in New York to help fund the installation at MIT of a cyclotron to be used primarily for medical purposes. As a result, the Markle Foundation provided a \$30,000 grant for the purchase and installation of the MIT cyclotron. The



cyclotron became operational in November 1940 and could produce therapeutic amounts of a mixture of ^{130}I (90%) and ^{131}I (10%). The half-lives of ^{130}I and ^{131}I are 12.4 h and 8.1 days, respectively.

ED, a female patient, is referred to Dr. Hertz's clinic with hyperthyroidism with no ophthalmopathy and a basal metabolic rate (BMR) of +30. On March 31, 1941, 2.1 mCi of the 130 I/ 131 I mixture is administered to ED, thus she becomes the first patient with thyroid disease to be treated with radioiodine. Upon the advice of Dr. Means, the radioactive treatment is "chased' with a dose of non-radioactive iodine. 17 days later, ED is treated with an additional 1.3 mCi of radioiodine. After therapy, her BMR decreased to -7. This initial experience was reported in May 1941 at the annual meeting of the American Society for Clinical Investigation. Over the next 2 years, 1941–1943, Hertz and Roberts treat 29 patients and administer post-therapy non-radioactive iodine to all of them. As they later reported [8], 20 of these patients were considered to have been cured

and 9 were not cured. The nine patients without resolution of hyperthyroidism underwent thyroidectomy, and upon pathologic examination of the thyroid glands, six had undergone some involution. There were no strong predictors of clinical response. The spreadsheets maintained by Dr. Hertz of these 29 patients are shown in Fig. 3.

In 1943, in the midst of World War II, Dr. Hertz decided to volunteer for military service. Upon his departure, responsibility for the MGH thyroid clinic was turned over to Earle Chapman, MD, who had been working in the clinic under the supervision of Dr. Hertz. While Dr. Hertz was absent, Dr. Chapman worked with

SERVES AVO.	S CASE-HOSRING	BM R PRIOR TO 7180	DOSAGE OF 1 and DATES GRADMINIS	70	MR PERM SUB-TOTAL WYRDIARCA	POST-OF BMR	TXNRAU WEAG-AT		TOTAL I IRRADI	THYROID ATION (*) RDAY	ESTIMATED THYROID WT. BEFORE J 180	FOLLOW	2D - 72 HRS. ING- THE ISTRATION - 1.130
1	ELIZABETH D. MGH-173954	+30	21mC 3-31-41 13mC 4-16-41	3.4 NC	(~5)(-7)	(-29)	34	INVOLUTION	470	660 240	35		20 28
5	LILLIAN R. MGH-308552	+35	5.7mC 7-16-141		ANNED	(-20)	3/	HYPERPLASI	4 1000	1150	40		27
10	GLADY5 B- MGH+12/922	+55	0.7mC 2-2- '42		(+3)	(-26)	24 30) 56	HYDERPEASU		80	60	Leo I	38
14	WILFRED B. MGH-363179	+50	15mC 7-15-42		(-15)	(-24)	55	HYPERPLASIA +INVOLUTION	1 050		60		7/
16	CARMELLA D. MGH-255820	+25	10mc 8-11-42		(-8)	(-24)	28	INVOLUTION		-	45		6
19	PETER C. MGH-369233	+65	15mC 8-25-42 8mC 3-8-43 5mC 3-9-43		(=8) 70 (=/3)	(+36) TO (-18)	35	SL.N YPERPLAD +INVOLUTION	2000		60		9
2	MARGARET B. 1464-300230	+35	14.5-10-41	=	NO	T OPL	YROT	oxicosis	160 110 120 100	140 100 120 100	40	4	74 • • 8 • 78
4	CAMILLE SCH®	+30	3.6m(7.14-41) 2.2m(7.31-41)	5.8 *C	EVES BE BMR (1	+2) OFF	NO MED.	GOTTER - 4 YRS	270	300 180	60		5
100	RUTH M.	+50	34mC 6-6-41		MISSIO				430	410	45	45	She S
3	MGH-304558	310	20mC 1-9-46 YPE	C.R.F	CENTLY				TOLET				
*0 B	-	<i>тніс т</i>	YRE ABLE II-A	AVALS		0F 20 = 2X1	2 7	NATIO	NA MAI	RETHERTED	946 100 Abul 200 Abul	* 1/ (MATES / KR (D) A 7	- energie
*0	CASE HOSP NO	THIC T T DATE O	YPE ABLE II-A ON B	ANALTA AST.	15/5 5 07 8 047	OF 20 E EXA Leve IODIDA	2 CA 1/4/	NATIO	i MAI	ACHARLI.	946 507 Abut	**************************************	9 JAYO 390 300
t o B	CASE HOSP NC	THIC T T DATE O DATE O DATE O DATE O	ABLE II-	ANALTA AST.	5 0F 5 0F 8 0FF 7 0F 7 0	0F 20 = 2X1	0 CA 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	NATIO	N MAI	ROHATED THRATED (gm)	946 707 801 110 401779 72 Halles	a moune	390
to B SHES NO. 6 7 8	CASE HOSP NC MICHAEL MOPA	THIC T 20050 2477 0 2477 0 2477 0 2477 0 2570 75700 7570 7570 7570 75700 75700 7570 7570	ABLE II-A ON B MADINGSTAT MADINGSTAT P-30-45 MC C 9-24-47	AMALY ASJ. ANTA ANTA ANTA ANTA ANTA ANTA ANTA ANT	15/5 5 07 8 000 1000 1000 1000 1000 1000 1000 100	01 20 2X1 10000 336/1 46 (~ 326/1	0 CA7 7A + 7	NATIO NATIO NATIO 100055 100055 100055 100055 100055 100055 100055 100055 100055 100055 100055 100055 100055 100055 10005 10	N MAI	2014/2013 1772010 W2 (gma) 45 45 40	946 ******* ******* ****** ***** ***** ****	320 320 280 260m 260m 300	390 300 280 220 250
to B SARES NO. 6 7 8 9	CASE HOSP NO MICHAEL MOPA	THIC T THIC T DATE: DATE: 2370C	YPE ABLE II-A ON 5 CON 5 CO	2000 1 2000 1 20	15/5 0 5 0 6 Break 9 Break 9 Break 1 All 1 All 1 - Break 1 - Break1 - Break 1 - Break 1 - Break 1 - Break 1 - Break	01 20 2X1 0 Ceve 100100 487 487 487 487 487 487 487 487 487 487	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	NA 7/0 means anas trest trest types Anos types	N NA	45 40 60	946 10 Aud 12 Aud 22 Aud 25 20 (11) 13 17	2 4004 320 280 26010 300 650	390 300 220 250 420
to B MD 6 7 8 9 11	CASE HOSP NO MICHAEL MOPA MICHAEL K MICHAEL K	THIC T THIC T DATE O 23 mic 23	YPE ABLE II-A ON 5 CON 5 CO	NAL 1A 51. 2007 13 +45 +45 +30 +30 +37	15/5 5 07 8 07 178 178 178 178 178 178 178	01 20 2X1 1000000	2 CA 2 237 1 2 2 2 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4	NA 7/0 meone 79 onors 89 treat 4 4 985 Anos 2 1995 1995	~ ~ ~	ACT4/3(1) Trinoin un (gm) 45 40 60 60	946 707 850 70 850 72 HOURS 35 22 30 (17 45 17 17	2 1001 320 280 260m 300 650 750	390 300 280 220 250 420 380
to B SARES NO. 6 7 8 9	CASE-HOSP NC MICHAEL MOPA MICHAEL K MICHAEL K MICHA	THIC T 20055 2437 C 2437 C 257 C 257 C 257 C 257 C	YPE ABLE II-A ON 5 CON 5 CO	2000 1 2000 1 20		0+ 20 25% 0 Leve 100000 33(- 32) 32(- 45(- 45(- 45(- 45(- 45(- 45(- 45(- 45	7 CA 2 7 A 2 7 A 4 7	NA 7/0 meone 79 onors 89 treat 4 4 985 Anos 2 1995 1995	N NA	45 40 60	946 10 Aud 12 Aud 22 Aud 25 20 (11) 13 17	2 4004 320 280 26010 300 650	390 300 220 250 420
+0 B B B B B B C C C C C C C C C C C C C	CASE HOSP NC CASE HOSP NC MCM852 X- MCM852 X- MCM852 X- MCM5227383 MCM5227383 MCM522733937 MCM523935 MCM5253 MCM5553 M	THIC 7 20050 DATE (233-00 233-00 233-00 233-00 233-00 233-00 233-00 233-00 25-00 25-00 12-00 23-00 12-00 23-00 23-00 25-00	ABLE II- ON 2 ON 7 ABLE II- ON 2 ABMANNON ABMANNNON ABMANNNON ABMANNON ABMANNON ABMANN	ANALY ASI 2000 173 465 465 465 480 450 457 455	15/5 07 5 07 8 000 7 000 7 000 7 000 7 00 7 00 7	01 20 28× 100000 42 42 42 42 42 42 42 42 42 42 42 42 42	2 CA A A A Z 2 2007 1 31 4 4 1 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	N/A T/O Imeons I	N NA. N 25 34 N N N N N N N N N N N N N N N N N N N	RCH4/2(1) 17/20/10/20/20/20/20/20/20/20/20/20/20/20/20/20	946 707 Aud 10.06777 72 AUARS 35 22 20(1) 15 17 17 17 26	2 100 1 320 280 260 260 300 650 750 950	390 300 280 220 250 420 380
+0 B SIRES NO. 6 7 8 9 11 12 13 15 15 17	CASE HOSP NO MC MAC L K. MC MC M	THIC 1 200550 2478 C 2305	ABLE II- ON 2 ON 7 MADINE II- ON 2 MADINAL STATE MADINAL STATE MADINAL STATE MADINAL STATE	-45 -45 -45 -45 -45 -50 -50 -50	15/5 5 5 07 9 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 1	01 20 28×1 00000 335 35 45 45 45 45 45 45 45 45 45 45 45 45 45	2 CA A A A Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	A/A T/O Imeone amas	N N N N N N N N N N N N N N N N N N N N	RCH4/3(1) Grund Teo (gm) W2 4-5 4-5 40 60 60 60 60 40 40 60 60 60 60 60 60 60 60 60 6	346 100 800 100 800 100 800 100 800 222 200 15 17 17 17 16 17 17 26 7/ 100 14	2 +000 320 280 260 260 260 260 300 650 750 950 750 2000 1300	390 300 280 220 250 420 380
+0 B mas ND 6 7 8 9 11 12 13 15 17 18	CASE-HOSP NU MC MAL M OPA SALES CONTROL MC MALL X MG M 2015 MC MALL X MG M 2015 MC MALL MC MC MC MALL MC MC MC MALL MC MC MC MC MALL MC MC M	THIC T THIC T T T T T T T T T T T T T T T T T T T	YPE ABLE II- ON 8 P 30-83 Sec 93-42 C 9-42 C 9-4		15/5 5 5 07 9 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 1	01-20 - 200 - 200	2 2 7 A 1 A 7 A 2 7 A 2 7 A 4 9 3 1 7 3 1 7 3 1 4 3 1 7 3 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7	AVA T/O. The one on order Street on order Street on order Street on order ANDS Street on order	N N N N N N N N N N N N N N N N N N N	ACTH (311) Friend (1) (1) (1) (1) (1) (1) (1) (1)	246 1000000 1100000 1100000 110000 11000 1100 140 150 150 150 150 150 150 150 15	2 +000 3280 2800 300 650 750 950 750 2000 1300 2000	390 300 280 220 250 420 380
+0 B SIRES NO. 6 7 8 9 11 12 13 15 15 17	CASE-HOSP NO. CASE-HOSP NO. MCCASE-HOSP NO. MCCASE-HOSP NO. MCCASE-CONTROL	THIC T THIC T DATE C DATE C 23000 23000 23000 250000 250000 25000 25000 25000 250	ABLE II- ON 2 ON 7 MADINE II- ON 2 MADINAL STATE MADINAL STATE MADINAL STATE MADINAL STATE	-45 -45 -45 -45 -45 -50 -50 -50	5 0,4 5 0,4 6 0,4 7 0,4	01 20 28×1 00000 335 35 45 45 45 45 45 45 45 45 45 45 45 45 45		A/A T/O Imeone amas	N MAN N N N N N N N N N N N N N N N N N N N	RCH4/3(1) Grund Teo (gm) W2 4-5 4-5 40 60 60 60 60 40 40 60 60 60 60 60 60 60 60 60 6	346 100 800 100 800 100 800 100 800 222 200 15 17 17 17 16 17 17 26 7/ 100 14	2 +000 320 280 260 260 260 260 300 650 750 950 750 2000 1300	390 300 280 220 250 420 380
+0 mes No. 6 7 8 9 11 12 13 15 17 18 20	CASE-HOSP NU MC MACL MOPA MC MACL K MC M	THIC T 30355 1000 1100 1100 1100 120	YPE ABLE II- ON 8 P 30-43 Sec 93-43 C 9-30-43 C 9	MALS ASJ. 1455 +300 +37 +55 +30 +355 +550 +355 +550 +355 +550	1515 500 000 2000 2000 2000 2000 2000 20	0, 20 2, 20 0,	2 C4 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1	AVA T/O Imme and Imme and <td< td=""><td>N MAN N N N N N N N N N N N N N N N N N N N</td><td>4.5 40 60 60 60 75 49 40 60 75 40 60 75 40 40 60 75 40 40 40 40 40 40 40 40 40 40 40 40 40</td><td>946 700 6607 720 68077 721 68078 22 85 22 85 22 15 17 17 17 17 26 17 17 17 17 26 14 15 20 14 15 20</td><td>3 room 3280 2280 26019 300 650 750 950 750 2000 1300 2000 1600</td><td>390 300 280 220 250 420 380</td></td<>	N MAN N N N N N N N N N N N N N N N N N N N	4.5 40 60 60 60 75 49 40 60 75 40 60 75 40 40 60 75 40 40 40 40 40 40 40 40 40 40 40 40 40	946 700 6607 720 68077 721 68078 22 85 22 85 22 15 17 17 17 17 26 17 17 17 17 26 14 15 20 14 15 20	3 room 3280 2280 26019 300 650 750 950 750 2000 1300 2000 1600	390 300 280 220 250 420 380
+ 00 B B B B B B B B B B B B B B B B B B	CASE-HOSP NU MC 8452 X MG 8452 X MG 8452 X MG 8452 X MG 85353 MC 8455 X MG 85353 MC 8455 MG 85354 MG 853547 MG 853547 MG 853547 MG 853547 MG 853547 MG 85354	THIC 1 THIC 1 TO 201520 23700 23700 73700 73700 73700 73700 73700 73700 73700 73700 73700 73700 738000 738000 738000 738000 738000 738000 738000 7380000000000	YPE ABLE II- ON 8 P 30-43 S 52 43 C - 9-42 C - 9-4	ANALY ASJ 2007 2007 2007 2007 2007 2007 2007 200	55/5 . 55 0 P 99 0 P 10	0, 2 (C) 2, 2 (X) 0, 2 (2 CAN 2 7 A A 2 7 A A 3 9 00 1 3 3 3 9 0 0 1 3 3 9 0 0 0 1 3 3 9 0 0 0 1 3 3 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	AVA T/O The one transmission The one transmission Stress Stress A105 Stress Stress Stress A105 Stress Stress A105 Stress Stress Stress Stress Stress Stress Stress Stress Stress		ADH (21) The state of the stat	946 500 0000 500 0000 500 0000 500 000 500 0000 500 00000 500 0000 500 0000 500 000 500 000 500 0000	2 rocet 200 200 200 200 300 650 750 950 2000 1300 2000 1600 2000	390 300 280 220 250 420 380
+ 00 B B B B B C C C C C C C C C C C C C	CASE-HOSP NU MC MAEL MOPA MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC M	THIC 1 THIC 1 TO 201520 23700 23700 73700 73700 73700 73700 73700 73700 73700 73700 73700 73700 738000 738000 738000 738000 738000 738000 738000 7380000000000	YPE ABLE II- ON 8 P 30-43 Sec 93-43 C 9-30-43 C 9	ANALY ASJ 2007 13 2007 10 2007 10 20000 10 2007 10 200	55555555555555555555555555555555555555	01 200 200 00 200 00 200 00 200 00 200 00	2 2 7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	NA 7/10 The one of antess Stress		ADH (21) The state of the stat	946 500 0000 700 0000 220 0000 221 220 000 135 17 17 17 26 17 17 26 17 17 26 17 17 26 17 17 26 18 20 18 18 20 18 18 18 18 18 18 18 18 18 18	2 road 200 200 200 200 300 650 750 950 2000 1300 2000 1600 2000 2200	390 300 280 220 250 420 380
+00 ministry 10 11 12 13 17 18 20 21 22 23 24 25	CASE HOSP NU MC MAEL MOPA CASE HOSP NU MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC M	THIC 1 THIC 1 23055 23075 23075 23075 23075 23075 23075 23075 25075 25075 25075 20075	YPE ABLE II- ON 8 P 30-43 S 52 43 C - 9-42 C - 9-4	AVALS ASI +45 +30 +35 +30 +35 +30 +35 +30 +35 +30 +35 +30 +35 +30 +45 +35	55555555555555555555555555555555555555	0, 2 (C) 2, 2 (X) 0, 2 (2 2 7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	NA 7/10 The one of antess Stress		ADH (21) The state of the stat	946 500 0000 500 0000 500 0000 500 000 500 0000 500 00000 500 0000 500 0000 500 000 500 000 500 0000	2 monte 320 200 200 200 300 650 750 200 750 2000 1600 2000 2000 500 500	390 300 280 220 250 420 380
+ 00 miles mil	CASE-HOSP NI MCMAEL & MCMAEL & MCMAEL	THIC 1 THIC 1 T DOFO DE SOUCH STOCE	YPE ABLE II- ON 2 TONO TON		55 0 P. S.	01 2 0 1 1 0 1 2 0 1 2 0 1 2 0 1 1 0	2 27 200 1 1 1 1 1 0 2 2 2 0 0 2 2 2 0 0 1 2 2 2 2	NA 77/0 The one of antess Strees	N N N N	ADH (21) THE ADD (22) 45 45 40 60 60 60 60 60 60 60 60 60 6	926 520 0000 520 0000 521 522 520 13 13 17 17 16 17 17 16 17 16 17 16 17 16 17 16 17 17 16 17 17 16 17 17 16 17 17 16 17 17 17 17 17 17 17 17 17 17	2 00000 2200 2200 200 200 250 250 2	390 300 280 220 250 420 380
+00 ministry 10 11 12 13 17 18 20 21 22 23 24 25	CASE HOSP NU MC MAEL MOPA CASE HOSP NU MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC MAEL K MC M	THIC 1 THIC 1 T DOFO DE SOUCH STOCE	YPE ABLE II- ON 2 COT 100- MADINAUSIAL SCOT 100- MADINAUSIAL SCOT 100- SCOT 100-	MALS: ASJ. 2000 445 450 450 450 455 455 455 455 455	5 0 Prove 5 0 Prove 0 Prove	0 F 2 C F F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2	2 C4 1 2 7 2 2 1 A 4 2 7 2 2 7 A 4 1 7 7 1 2 7 2 2 7 A 4 1 7 7 1 2 7 2 2 7 A 4 1 7 7 1 2 7 2 7 A 4 1 7 7 1 2 7 2 7 A 4 1 7 7 1 2 7 2 7 A 4 1 7 7 1 2 7 2 7 A 4 1 7 7 1 2 7 2 7 A 4 1 7 7 7 1 2 7 A 4 1 7 7 7 7 1 2 7 A 4 1 7 7 7 7 7 1 2 7 A 4 1 7 7 7 7 7 7 7 A 4 1 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	NA T/O The one The one Exest		ACH (2] J. Transford W2 (3) (3) (4) 45 45 40 60 60 60 60 60 60 60 60 60 6	926 500 0000 100 0000 100 000 100 0000 100 000 100 0000 100 0000 100 0000 1000 100 000 100 000 100 000 1000	2 00000 2200 2200 200 200 200 200 2000 2	390 300 280 220 250 420 380

Fig. 3 Reproductions of pages from Dr. Hertz's laboratory notebook showing the result of his first 29 patients. Table 1 (Fig. 3a) lists 9 patients that were "not cured" and subsequently received surgery including ED, the first patient treated with radioiodine for thyroid disease in 1941. Table 2 (Fig. 3b) lists 20 patients that were cured and required no further treatment

Evans to continue to treat thyroid patients with radioiodine. However, in these cases, the administration of radioiodine was not followed with a dose of non-radioactive iodine.

After the war, Dr. Hertz worked to re-establish himself in the medical community in Boston. After being unsuccessful in his attempt to rejoin the staff at the MGH, he joined the medical staff of the Beth Israel Hospital. During this time, it came to Dr. Hertz's attention that Chapman and Evans planned to publish the results in 22 patients they had treated with radioiodine during the time Hertz was in the service, and that a manuscript without recognition of the work by Hertz and Roberts had been submitted to the Journal of the American Medical Association. Hertz and Roberts reported on their initial 29 patients in the same issue of the journal, just previous to the Chapman and Evans paper. This resulted in the unusual circumstance of two manuscripts on the same topic from the same institution with no overlapping authorship being published back-to-back in the same medical journal [8, 9]. Later the same year, Dr. Seidlin and his group at Montefiore Hospital in New York also reported in the Journal of the American Medical Association on the use of radioiodine to treat 23 patients with metastatic thyroid cancer [10]. Dr. Seidlin had consulted with Dr. Hertz regarding this research. In 1948, Means published a review article on the use of radioiodine in the diagnosis and treatment of thyroid disease [11]. In the article, Means recognized the initial treatment with radioiodine of patients with Graves' disease by Hertz and Roberts as reported at the American Society for Clinical Investigation in 1941. In this article, he also recognized the subsequent work in this realm by Hamilton and Lawrence as well as Chapman and Evans.

Conclusions

We have researched these events to the best of our ability, given that they happened over 70 years ago, but we are confident that we have reported the proper sequencing of events so essential to the history of nuclear medicine. Not only do these events mark the first therapeutic use of radioiodine, but also the use of targeted radionuclide therapy to demonstrate the fundamental principles of both molecular nuclear medicine and theranostics. 75 years later, we find ourselves in an era of rebirth for radionuclide therapy, with the recent introductions of ²²³Ra dichloride for treatment of bone metastases and¹⁷⁷Lu-labeled agents for treatment of both neuroendocrine tumors and prostate cancer. The use of ¹⁷⁷Lu-labeled agents opens up the potential for new "theranostic" applications, where, much as with radioactive iodine in the management of thyroid disease, the same agent can be used for both diagnostic imaging and therapy. The field of nuclear medicine is indebted to Dr. Hertz, his collaborators, and other early pioneers for their scientific vision, courage, and persistence.

Acknowledgements

The authors would like to acknowledge and thank Barbara Hertz for providing the material for the figures in this manuscript.

Funding

The authors received no funding for the work associated with this paper.

Authors' contributions

All authors made equal and substantial contributions to the conception and design of this manuscript, were directly involved in drafting and revising of the manuscript, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Competing interests

The authors have competing interests to declare, financial or otherwise, regarding the content of this manuscript.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Radiology, Harvard Medical School, Boston, MA, USA. ²Department of Radiology, Boston Children's Hospital, Boston, MA, USA. ³Department of Radiology, Mount Auburn Hospital, Boston, MA, USA. ⁴Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.

Received: 28 January 2017 Accepted: 12 April 2017 Published online: 27 April 2017

References

- Ell PJ. The contribution of medical physics to nuclear medicine: a physician's perspective. EJNMMI Phys. 2014;1(1): 3. doi:10.1186/2197-7364-1-3.
- 2. Joliot F, Curie I. Artificial production of a new kind of radio-element. Nature. 1934;133(3354):201-2.
- 3. Means J, Holmes G. Further observations on the Roentgen-Ray treatment of toxic goiter. Tr A Am Phys. 1922;37:198.
- 4. de Hevesy G. Nobel lecture: some applications of isotopic indicators. 1943. www.nobelprize.org/noble_prizes/ chemistry/laureates/1943/
- Hertz S, Roberts A, Evans RD. Radioactive iodine as an indicator in the study of thyroid physiology. Exp Biol Med. 1938;38(4):510–3.
- Hamilton JG. The rates of absorption of radio-sodium in normal human subjects. Proc Natl Acad Sci U S A. 1937; 23(9):521–7.
- Hamilton JG, Soley MH. A comparison of the metabolism of iodine and of element 85 (Eka-Iodine). Proc Natl Acad Sci U S A. 1940;26(8):483–9.
- Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology: VII. The use of radioactive iodine therapy in hyperthyroidism. JAMA. 1946;131(2):81–6.
- 9. Chapman EM, Evans RD. The treatment of hyperthyroidism with radioactive iodine. J Am Med Assoc. 1946;131:86–91.
- Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132(14):838–47.
- 11. Means JH. The use of radioactive iodine in the diagnosis and treatment of thyroid diseases. Bull N Y Acad Med. 1948;24(5):273–86.

Submit your manuscript to a SpringerOpen[™] journal and benefit from:

- ► Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- ► High visibility within the field
- ► Retaining the copyright to your article

Submit your next manuscript at > springeropen.com